Connect With Us

800-350-8656

9700 Great Seneca Hwy
Rockville, MD 20850

info@3CLogic.com
sales@3CLogic.com
"enhanced reporting"
Not only did we get all the features of our old system with 3CLogic, we got enhanced reporting features that are pictorial, graphical and intuitive.
-Mohit Adalkha,
Assistant General Manager,
Spanco BPO
"endless opportunity"
Since deploying 3CLogic’s Contact Center solution, we are presented with an endless opportunity for business and sales growth.
-Dale McCrary,
VP of Technology,
Sopra Brands
"state of the art product"
3CLogic has come out with a state of the art product that is based on a combination of Cloud Services and Distributed Computing Architecture.
-Alvaro Ramirez,
Cediva

Cloud Call Center Community Featured Article

TMCNet: Alkermes Unveils Long-Acting Injectable Proprietary Platform for Treatment of Schizophrenia and Other CNS Disorders

[February 04, 2010]

Alkermes Unveils Long-Acting Injectable Proprietary Platform for Treatment of Schizophrenia and Other CNS Disorders

WALTHAM, Mass. --(Business Wire)-- Alkermes, Inc. (NASDAQ: ALKS) today announced that it has developed a novel, proprietary LinkeRx™ technology platform to enable the creation of injectable extended-release versions of antipsychotics and other central nervous system (CNS) therapies. The company's lead candidate that leverages this platform, designated as ALKS 9070, is a once-monthly, injectable, extended-release version of aripiprazole for the treatment of schizophrenia. Aripiprazole is commercially available under the name ABILIFY® for the treatment of a number of CNS disorders.


"We are pleased to build upon our expertise in developing long-acting platforms and therapies to bring forward a once-monthly version of aripiprazole, a widely prescribed product with a proven safety and efficacy profile," stated Dr. Elliot Ehrich, Chief Medical Officer of Alkermes. "Multiple studies have shown that long-acting therapies in the treatment of schizophrenia can lead to improved patient outcomes and reduced costs. An additional extended-release injectable medication would provide another valuable option for patients and physicians to manage this serious, chronic disease." Based on encouraging preclinical results, ALKS 9070 is expected to enter the clinic in the second half of calendar 2010. A number of patent applications have been submitted to the U.S. Patent and Trademark Office to protect the LinkeRx technology and ALKS 9070.

Alkermes' LinkeRx technology uses proprietary linker-tail chemistry to create new molecules derived from known agents. The resulting New Molecular Entities are designed to have improved clinical utility, manufacturing and ease-of-use compared to other long-acting medications. The LinkeRx technology platform has the potential to be applied to a wide range of therapeutic molecules for the treatment of CNS disorders, including schizophrenia, depression and epilepsy, where there is a strong clinical and patient need for long-acting medication options to improve treatment outcomes.

"We are pleased to unveil this novel technology and a compelling lead product candidate because we believe both are valuable assets for the company," commented Richard Pops, Chief Executive Officer of Alkermes. "Alkermes' expertise in developing safe and effective long-acting therapeutics uniquely positions us to develop a once-monthly version of aripiprazole." Alkermes is a leader in developing long-acting medications and has an established portfolio of CNS products, including RISPERDAL® CONSTA®, VIVITROL®, ALKS 33 and ALKS 36. Alkermes focuses on therapies for widespread, chronic diseases, including CNS disorders such as addiction, pain and mental health disorders, where the company believes there is a strong opportunity for long-acting medications to offer significant new treatment options for patients.

About Schizophrenia Schizophrenia is a chronic, severe and disabling brain disorder. The disease is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions and social withdrawal), as well as by disorganized thinking. An estimated 2.4 million Americans have schizophrenia, with men and women affected equally. Worldwide, it is estimated that one person in every 100 develops schizophrenia, one of the most serious types of mental illness.

About Alkermes Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes developed, manufactures and commercializes VIVITROL® for alcohol dependence and manufactures RISPERDAL® CONSTA® for schizophrenia and bipolar I disorder. Alkermes' robust pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Waltham, Massachusetts, Alkermes has a research facility in Massachusetts and a commercial manufacturing facility in Ohio.

Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, those relating to: the patentability of the company's new LinkeRx technology platform and ALKS 9070, development activities for ALKS 9070, including its entering the clinic in the second half of 2010, and the therapeutic potential of ALKS 9070 for the treatment of schizophrenia. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and the company's business is subject to significant risk and uncertainties and there can be no assurance that its actual results will not differ materially from its expectations. These risks and uncertainties include, among others: whether the company will continue to pursue the development of the new proprietary platform; whether the patent applications underlying the new LinkeRx technology and ALKS 9070 will be issued and enforceable against competing products; whether the clinical development discussed in this release will be completed on time or at all; potential changes in cost, scope and duration of such clinical development; whether ALKS 9070 will demonstrate sufficient efficacy and safety; and decisions by the U.S. Food and Drug Administration regarding the product candidate. For further information with respect to factors that could cause the company's actual results to differ materially from expectations, reference is made to the reports the company filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements made in this release are made only as of the date hereof and the company disclaims any intention or responsibility for updating predictions or financial expectations contained in this release.

VIVITROL® is a registered trademark and LinkeRx™ is a trademark of Alkermes, Inc.; RISPERDAL® CONSTA® is a registered trademark of Janssen-Cilag group of companies and ABILIFY® is a registered trademark of Otsuka Pharmaceutical Co., Ltd.

[ Back To Homepage ]

Resources

Top 5 Disadvantges of Outsourcing
All businesses alike, no matter what goods and services they provide, strive for 100% customer satisfaction. Any decrease in customer satisfaction rates, whether it is through customer service or product interactions can be detrimental to your company's success.
Read More »
The Five Most Dangerous Mistakes Sales Organizations Make
Studies show that the odds of contacting a lead if called in 5 minutes versus 30 minutes drop 100 times. The odds of qualifying a lead if called in 5 minutes versus 30 minutes drop 21 times.
Read More »
Remote Agents in the Cloud!
As an upcoming business owner, you want to make sure you decrease your costs and boost your profits as much as possible. If you run an in-office call center business, you need to worry about managing agents as well as all of the necessary equipment to administer your leads.
Read More »

Cloud Based Solutions Brochure


areg
Contact Centers Made Simple by 3CLogic

3CLogic News

Online Certification Tests from 3CLogic Enhance Quality Assessments for Contact Center Agents and Managers
November 19, 2011
Launch of new 3CLogic University facilitates business growth with certified Call Center staff. Online tests assess agents’ and managers’ contact center knowledge.
Read More »
3CLogic to Double Efficiency of Contact Centers with the Addition of Blended and Multi-Channel Functionalities
October 26, 2011
3CLogic removes barriers for call centers to move to a cloud based service with multi-channel interactions including email, text, voice, and chat. Call blending in the cloud can increase new revenues for businesses by as much as 40%.
Read More »

White Papers

Hosted Contact Centers
In a contemporary era, communication with global citizens calls for global technologies. This means that the hosted contact centers need costly equipment and solutions that cater to modern day needs. They need to be constantly upgraded to give a satisfying experience to the customers.
Read More »

3CLogic Videos